Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$28.64 USD

28.64
25,167,304

-0.28 (-0.97%)

Updated May 17, 2024 04:01 PM ET

After-Market: $28.67 +0.03 (0.10%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 24% (189 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Swarup Gupta headshot

5 Dogs of the Dow Stocks for 2017

After a dismal 2015, during which it lost 2.3%, the Dow has just completed a spectacular year.

    Inotek (ITEK) Down on Poor Phase III Glaucoma Drug Data

    Shares of Inotek Pharmaceuticals Corporation (ITEK) plunged 71.3% after the company announced that its lead candidate trabodenoson failed to meet the primary endpoint in a phase III trial.

      4 Reasons Why Pfizer (PFE) Could be a Great Pick in 2017

      Pfizer's shares surpassed that of large-cap pharma industry in 2016. The stock rose 0.6% in 2016.

        Mylan (MYL) Announces Multiple Generic Launches in the U.S.

        Mylan (MYL) announced quite a few generic launches in the U.S. in Dec 2016.

          ARIAD Stock Beats Industry in 2016, Iclusig Sales Strong

          Shares of ARIAD Pharma surged 98.4% year to date and outperformed the Zacks classified Medical-Drugs industry that declined 25.4%.

            Merck (MRK) Does Well in 2016: Reasons for Outperformance

            Merck & Co. Inc.'s (MRK) share price is up 12.1%, so far this year.

              Aerie (AERI) Rhopressa Regulatory Application Delayed Again

              Aerie (AERI)'s NDA for lead candidate, Rhopressa, gets delayed again due to delay on the manufacturer's part.

                Portola Betrixaban Accepted for Review in U.S. & EU, Stock Up

                Shares of Portola (PTLA) surged 33.8% after the FDA granted priority review to anticoagulant, betrixaban. Betrixaban was also accepted by the EMA for review.

                  Swarup Gupta headshot

                  Dow 30 Stock Roundup: Nike Beats, Coca-Cola to Buy AB InBev's Stake in CCBA

                  The Dow endured a turbulent week as the post-election rally encountered several roadblocks.

                    The Zacks Analyst Blog Highlights: Pfizer, Microsoft, Bank of America, Oracle and Nike

                    The Zacks Analyst Blog Highlights: Pfizer, Microsoft, Bank of America, Oracle and Nike

                      Pfizer Ibrance sNDA Accepted by FDA under Priority Review

                      Pfizer Inc.'s (PFE) supplemental new drug application (sNDA) to convert accelerated approval for its breast cancer drug, Ibrance, to regular approval was accepted by the FDA under priority review.

                        J&J Resumes Talks with Actelion: Did Sanofi Just Lose Out?

                        In an interesting turn of events, Johnson & Johnson (JNJ) announced that it is once again discussing a possible transaction with Swiss biotechnology company Actelion Ltd. (ALIOF).

                          Pfizer (PFE) Nimenrix Vaccine's Label Expanded in the EU

                          Pfizer Inc. (PFE) announced that the European Commission has approved an expanded indication for its meningococcal vaccine, Nimenrix.

                            Allergan to Buy LifeCell to Boost Regenerative Medicine Suite

                            Allergan plc (AGN) announced that it has signed a definitive agreement to acquire LifeCell, the regenerative medicine unit of Texas-based privately held company Acelity for $2.9 billion in cash.

                              Merck Keytruda Gets CHMP Nod for First-Line Lung Cancer

                              Merck & Co., Inc. (MRK) announced that its anti-PD-1 therapy, Keytruda, was rendered a positive opinion in the EU for the first-line treatment of metastatic lung cancer.

                                Pfizer Chantix Label Warning Lifted in U.S.; to Add New Data

                                Pfizer, Inc. (PFE) announced that the FDA has lifted a boxed warning about neuropsychiatric side effects from the label of its smoking cessation drug, Chantix.

                                  Arpita Dutt headshot

                                  Pharma Stock Roundup: Lilly Up on Guidance, Merck Awarded $2.54B in HCV Case

                                  Lilly (LLY) was among the biggest gainers among major pharma stocks last week with the company providing better-than-expected guidance for 2017.

                                    Swarup Gupta headshot

                                    Dow 30 Stock Roundup: Boeing, GE Raise Dividends; ExxonMobil Gets New CEO

                                    The Dow enjoyed a week of strong gains on rising expectations about the likely industry friendly policies of the Trump administration.

                                      Big Pharma Face Off: Is Merck More Attractive than J&J?

                                      Johnson & Johnson (JNJ) and Merck & Co. Inc. (MRK) are some of the better-performing large-cap pharma stocks

                                        Pfizer: FDA Approves Eczema Ointment; Xtandi Fails Study

                                        Pfizer, Inc. (PFE) announced that it received FDA approval for crisaborole topical ointment to treat mild-to-moderate eczema, or atopic dermatitis, in patients two years and older. The ointment will be sold under the brand name Eucrisa.

                                          Will Buyback ETFs Gain Big on Overseas Cash Repatriation?

                                          With Donald Trump winning the U.S. elections, a plethora of buybacks are expected to hit the market.

                                            J&J (JNJ) Ends Deal Talks with Actelion: Will Sanofi Gain?

                                            On Tuesday, Johnson & Johnson (JNJ) announced that it has ended talks regarding a possible transaction with Swiss biotechnology company, Actelion Ltd. (ALIOF), reportedly for a disagreement over the purchase price.

                                              Lilly/AstraZeneca Expand Alzheimer Disease Collaboration

                                              Eli Lilly and Company (LLY) and AstraZeneca plc (AZN) expanded their existing collaboration to develop the second treatment for Alzheimer's disease, MEDI1814

                                                Pfizer (PFE) Fined for Price Hike of Anti-Epilepsy Drug in UK

                                                Pfizer (PFE) fined for hiking price of an anti-epilepsy drug by up to 2,600% by the Competition and Markets Authority of the UK.

                                                  Arpita Dutt headshot

                                                  Should Biotech Investors Worry About Donald Trump?

                                                  It looks like biotech investors may have heaved a sigh of relief a bit too early when Presidential election results were announced last month.